Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report)’s share price was up 11.4% during mid-day trading on Thursday . The company traded as high as $2.63 and last traded at $2.63. Approximately 122 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 977 shares. The stock had previously closed at $2.36.
Silence Therapeutics Price Performance
The stock has a 50 day moving average of $2.10 and a 200-day moving average of $1.83.
Silence Therapeutics Company Profile
Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.
The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.
Featured Articles
- Five stocks we like better than Silence Therapeutics
- Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
- Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
- Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
- Water Infrastructure: Why This Boring Sector Could Get Exciting
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
